|Articles|April 17, 2019

Common Food Additive May Hinder Flu Vaccine Effectiveness

Could an additive in your food be messing with the immune process that helps you fight off the flu after receiving the influenza vaccine?

Although the seasonal influenza vaccine remains an important tool in the prevention of flu transmission, and can mitigate the virus’ harsh symptoms if it is contracted, the illness still causes thousands of hospitalizations and deaths every year in the US. Vaccinated individuals are less likely to contract the flu, but it does happen. Now, a team of investigators at Michigan State University in East Lansing say they’ve discovered one possible reason for a loss of vaccine efficacy — a common food additive called Tert-butylhydroquinone, or tBHQ.

TBHQ is added to a variety of foods, including crackers, chips, cooking oils, and frozen meats and fish, to extend freshness. According to Cheryl Rockwell, PhD, an associate professor in pharmacology and toxicology and leader of the study team, it may not even be included on the list of ingredients even though chances are high that you consume it. “Nearly everyone who lives in industrialized countries has tBHQ in their diet,” Rockwell told Contagion®. “It is used to stabilize oils and fats in numerous food types that are commonly found at the grocery store.” But in mouse studies recently conducted by Rockwell and her team, tBHQ had a significant impact on the activation of T cells responsible for fighting off the flu.

According to Robert Freeborn, a fourth-year graduate student who also led the study, previous studies the team conducted demonstrated that tBHQ negatively impacted CD4 T cell activation. To test their theory that tBHQ impairs the T cell response to the flu, mice were funneled into 2 groups: 1 group was fed a substance containing tBHQ, and the other was fed a substance without tBHQ. Two weeks later, both groups were given a dose of influenza. The group receiving tBHQ had notable delays in T cell activation and lower levels of viral clearance. The team also discovered, after infecting the mice with an additional (different) strain of flu virus, that the tBHQ group took twice as long—6 days versus 3–to begin recovering from this second bout of flu. “This suggests that tBHQ impaired the memory response to infection with related strains of influenza virus, which would be expected to correlate with reduced vaccination efficacy,” Freeborn wrote in a recent summary of the study’s findings that he presented at the 2019 Experimental Biology meeting.

As far as how much tBHQ is needed to tamp down immune activation, the answer is: not much. “Our study shows that a low dose of tBHQ (0.0014%) hinders the immune response to influenza infection,” Rockwell said. “This concentration is equivalent to what is found in certain human and animal foods.” In his presentation, Freeborn noted that although the allowable daily intake of tBHQ is 0.7 mg/kg/day, estimates using sample diets indicate that people could be eating as much as 7.7 mg/kg/day, or 1,100% of the recommended amount.

The exact mechanism by which tBHQ impacts T cells is not yet known. “Our in vitro studies suggest that activation of a protein called Nrf2 may play a role in how these effects occur,” Rockwell said. “But subsequent studies are needed to determine this.” No further clinical studies on the effect of tBHQ and flu are planned at the moment, although Rockwell and her team are continuing to study tBHQ’s effect on human immune cells. One of her past studies found a correlation between tBHQ and human allergies, and tBHQ also has been controversial for its possible role as a cancer-causing agent.


Related to this article

REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.